DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aerospan (Flunisolide Hemihydrate Inhalation) - Drug Interactions, Contraindications, Overdosage, etc



AEROSPAN drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.


Flunisolide hemihydrate infused intravenously at doses up to 4000 mcg/kg in mice, rats and dogs (approximately 25, 50 and 170 times, respectively, the maximum recommended daily inhalation dose in adults and approximately 30, 60 and 200 times, respectively, the maximum recommended daily inhalation dose in children on a mg/m2 basis) produced no mortality.

In a double-blind, placebo-controlled study, 18 mg of flunisolide hemihydrate was administered via the CFC formulation over a three-hour period (nine times the maximum labeled daily dose) in 94 patients with acute asthma, and no clinically deleterious effects were observed.


AEROSPAN Inhalation Aerosol is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

Hypersensitivity to flunisolide or any of the ingredients of this preparation contraindicates the use of AEROSPAN Inhalation Aerosol.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015